AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
CIPLA, India's second largest drugmaker, has cut the prices of its anti-HIV medicines following the government's decision to exempt nine such drugs from excise duty.
Cipla's brands like Stavir, Lamivir, Nevimune, Dinex, Indivan, Triomune, Efavir, and Duovir will now cost 10 to 11 per cent lesser than before the Union Budget.
The government exempted nine anti-HIV drugs namely lamivudine, stavudine, didanosine, saquinavir, ritonavir, indinavir, efavirenz, nelfinavir, and nevirapine from a 16 per cent excise duty in the latest budget.
A Cipla executive said it would take about a week for stock at the new prices to be available to consumers. Cipla …